Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IAM1363 |
| Synonyms | |
| Therapy Description |
IAM1363 irreversibly inhibits wild-type and mutant ERBB2 (HER2), including exon 20 insertions, potentially leading to tumor growth inhibition (Cancer Res (2023) 83 (7_Supplement): 4034). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IAM1363 | IAM-H1|ENT-H1 | HER2 Inhibitor 44 | IAM1363 irreversibly inhibits wild-type and mutant ERBB2 (HER2), including exon 20 insertions, potentially leading to tumor growth inhibition (Cancer Res (2023) 83 (7_Supplement): 4034). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06253871 | Phase I | IAM1363 IAM1363 + Trastuzumab | A Phase 1/1b Study of IAM1363 in HER2 Cancers | Recruiting | USA | IRL | ESP | 0 |